Back to search
Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 trials you may qualify forThis phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders wi…
This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A in solid tumors included the dose esc…
The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.